AMG424 was selected out of a panel of CD38 x CD3 BsAbs based on its ability to effectively eliminate cancer cells expressing high and low levels of CD38, but with attenuated cytokine release (because of relatively low CD3 binding affinity) [24]. Here, CD38 is linked to cancer.